AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6212962 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg + Ethanol 50 g
Number of subjects: 6
Study 6212962 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg + Ethanol 50 g
Number of subjects: 6
Study 6212962 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Ethanol 50 g
Number of subjects: 6
Study 30106333 — intervention group
Group type: EXPERIMENTAL
Intervention: Teethmate AP paste (TMAP)
Number of subjects: 40
Study 30106333 — intervention group
Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer (TMD)
Number of subjects: 40
Study 30106333 — intervention group
Group type: COMPARATOR
Intervention: NaF (0.21% means 950 ppm)
Number of subjects: 40
Study 30106333 — intervention group
Group type: COMPARATOR
Intervention: No desensitizer treatment
Number of subjects: 40
Study 29724222 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional IPV only
Number of subjects: 935
Study 29724222 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and emotional IPV
Number of subjects: 935
Study 29724222 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional IPV
Number of subjects: 935
Study 29724222 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical IPV
Number of subjects: 935
Study 26499112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 ml of 0.5% hyperbaric bupivacaine at 5 °C (group I, n = 50)
Number of subjects: 100
Study 26499112 — intervention group
Group type: COMPARATOR
Intervention: 1.8 ml of 0.5% hyperbaric bupivacaine at 23 °C (group II, n = 50)
Number of subjects: 100
Study 22092804 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone mineral (DBBM)
Number of subjects: 30
Study 22092804 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic hydroxyapatite in a collagen matrix (S-HA)
Number of subjects: 30
Study 20581690 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 243
Study 20581690 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated vaccine (TIV)
Number of subjects: 243
Study 20581690 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LAIV and TIV
Number of subjects: 243
Study 20581690 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 243
Study 18398813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (12.5% concentration)
Number of subjects: 49
Study 18398813 — intervention group
Group type: EXPERIMENTAL
Intervention: De-alcoholised red wine
Number of subjects: 49
Study 16329604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine chelated iron (II)
Number of subjects: 120
Study 16329604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12437796 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Assessment of Functioning (GAF)
Number of subjects: 0
Study 12437796 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment of Positive Symptoms (SAPS)
Number of subjects: 0
Study 12437796 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment of Negative Symptoms (SANS)
Number of subjects: 0
Study 12437796 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Behaviour Schedule
Number of subjects: 0
Study 12542209 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine (120 mg/day for 4 weeks)
Number of subjects: 77
Study 12542209 — intervention group
Group type: COMPARATOR
Intervention: Zinc sulfate (400 mg/day for 4 weeks)
Number of subjects: 77
Study 10196910 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended formalized information by an anaesthetic nurse
Number of subjects: 101
Study 10196910 — intervention group
Group type: COMPARATOR
Intervention: Standard pre- and postoperative information by a ward nurse
Number of subjects: 101
Study 7899404 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (1.5-2.0 mg/h i.v.)
Number of subjects: 46
Study 7899404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 2535284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes in horizontal position
Number of subjects: 14
Study 2535284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes with 15 degrees head-up tilt
Number of subjects: 14
Study 2535284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes with 15 degrees head-down tilt
Number of subjects: 14
Study 381094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1084
Study 31614214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI) - 6 sessions delivered via telephone
Number of subjects: 0
Study 31614214 — intervention group
Group type: COMPARATOR
Intervention: Education Only Control (EOC) - 6 sessions delivered via telephone
Number of subjects: 0
Study 27995641 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm intended by perpetrator and perceived as intended to harm by target (II condition)
Number of subjects: 656
Study 27995641 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm not intended by perpetrator but perceived as intended to harm by target (NI condition)
Number of subjects: 656
Study 27995641 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm intended by perpetrator but not perceived as intended to harm by target (IN condition)
Number of subjects: 656
Study 27995641 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm not intended by perpetrator and not perceived as intended to harm by target (NN condition)
Number of subjects: 656
Study 27995641 — intervention group
Group type: COMPARATOR
Intervention: Control condition (C condition) which did not state any actual or perceived harmful intention
Number of subjects: 656
Study 25974971 — intervention group
Group type: EXPERIMENTAL
Intervention: WFG-LASIK
Number of subjects: 34
Study 25974971 — intervention group
Group type: COMPARATOR
Intervention: WFO-LASIK
Number of subjects: 34
Study 25974971 — intervention group
Group type: EXPERIMENTAL
Intervention: WFG-LASIK and WFO-LASIK
Number of subjects: 34
Study 23063111 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training (90 min, twice a week for six months)
Number of subjects: 50
Study 23063111 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 21958447 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH-IT (Internet-based intervention for depression)
Number of subjects: 0
Study 19450991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 78
Study 19450991 — intervention group
Group type: COMPARATOR
Intervention: Conventional median total sternotomy
Number of subjects: 78
Study 17178823 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased participation goal setting (n = 101)
Number of subjects: 201
Study 17178823 — intervention group
Group type: COMPARATOR
Intervention: Usual practice goal setting (n = 100)
Number of subjects: 201
Study 15124190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic assessment of clubfoot during treatment
Number of subjects: 42
Study 15124190 — intervention group
Group type: COMPARATOR
Intervention: Sonographic assessment of clubfoot
Number of subjects: 42
Study 11495260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin reaction sizes of 5-9 mm
Number of subjects: 241
Study 11495260 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin reaction sizes of 0-4 mm
Number of subjects: 241
Study 9209648 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM/ALK fusion cDNA detected in RNA from whole lymph node tissue
Number of subjects: 16
Study 9209648 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM/ALK fusion sequences amplified from single H-RS cells
Number of subjects: 16
Study 7960025 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide with felodipine
Number of subjects: 12
Study 7960025 — intervention group
Group type: COMPARATOR
Intervention: Felodipine alone
Number of subjects: 12
Study 3296728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirmenol (50 mg intravenous bolus followed by 2.5 mg/min infusion)
Number of subjects: 30
Study 3296728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (75 mg intravenous bolus followed by 3 mg/min infusion)
Number of subjects: 30
Study 3296728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29955020 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray group (EBUS-GS with fluoroscopy)
Number of subjects: 31
Study 29955020 — intervention group
Group type: COMPARATOR
Intervention: Non-X-ray group (EBUS-GS without fluoroscopy)
Number of subjects: 31
Study 26647072 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment guidance based on continuous glucose monitoring (CGM) data
Number of subjects: 34
Study 26647072 — intervention group
Group type: COMPARATOR
Intervention: Advice based on blood glucose and glycosylated haemoglobin (HbA1c) levels (nonintervention group)
Number of subjects: 34
Study 25241887 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free paclitaxel-eluting stent (PF-PES)
Number of subjects: 165
Study 25241887 — intervention group
Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stent (PB-PES)
Number of subjects: 165
Study 22552026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat oxidation in Asians
Number of subjects: 34
Study 22552026 — intervention group
Group type: COMPARATOR
Intervention: Dietary fat oxidation in whites
Number of subjects: 34
Study 22552026 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h fat oxidation in Asians
Number of subjects: 34
Study 22552026 — intervention group
Group type: COMPARATOR
Intervention: 24-h fat oxidation in whites
Number of subjects: 34
Study 22552026 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate oxidation in Asians
Number of subjects: 34
Study 22552026 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate oxidation in whites
Number of subjects: 34
Study 22552026 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein oxidation in Asians
Number of subjects: 34
Study 22552026 — intervention group
Group type: COMPARATOR
Intervention: Protein oxidation in whites
Number of subjects: 34
Study 22552026 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percentage in Asians
Number of subjects: 34
Study 22552026 — intervention group
Group type: COMPARATOR
Intervention: Body fat percentage in whites
Number of subjects: 34
Study 22552026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass index in Asians
Number of subjects: 34
Study 22552026 — intervention group
Group type: COMPARATOR
Intervention: Fat-free mass index in whites
Number of subjects: 34
Study 20973155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (OX) 20 mg/d
Number of subjects: 60
Study 20973155 — intervention group
Group type: COMPARATOR
Intervention: Morphine (MO) 30 mg/d
Number of subjects: 60
Study 18540331 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules (T-long) administered in the morning
Number of subjects: 18
Study 18540331 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules (T-long) administered in the evening
Number of subjects: 18
Study 18540331 — intervention group
Group type: COMPARATOR
Intervention: 200 mg tramadol extended-release capsules (T-long) administered in the morning and evening
Number of subjects: 18
Study 15787899 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus weekly telephone contact by a diabetes nurse educator (DNE) for 6 months.
Number of subjects: 46
Study 15787899 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes management (control group).
Number of subjects: 46
Study 12736400 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron-folate supplementation
Number of subjects: 2088
Study 12736400 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron-folate supplementation
Number of subjects: 2088
Study 12736400 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 2088
Study 11014412 — intervention group
Group type: EXPERIMENTAL
Intervention: IY-81149 10 mg
Number of subjects: 60
Study 11014412 — intervention group
Group type: EXPERIMENTAL
Intervention: IY-81149 20 mg
Number of subjects: 60
Study 11014412 — intervention group
Group type: COMPARATOR
Intervention: IY-81149 5 mg
Number of subjects: 60
Study 11014412 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 60
Study 8676802 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HPD) 1.6 g/kg BW + Enalapril (ENAL) 10 mg/day
Number of subjects: 8
Study 8676802 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LPD) 0.8 g/kg BW
Number of subjects: 8
Study 1450309 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA device Prominject with fentanyl demand doses of 34 micrograms, lockout time of 1 min, no concurrent infusion
Number of subjects: 80
Study 1450309 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA device ODAC with fentanyl demand doses of 34.5 micrograms, lockout time of 5 min, fixed-rate infusion of 4 micrograms/h
Number of subjects: 80
Study 1450309 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA device Prominject with tail-dose, fixed-rate infusion of 17 mg/h for a maximum of 60 minutes following a valid demand
Number of subjects: 80
Study 1450309 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA device ODAC with adaptive-rate infusion starting with 4 micrograms/h, adapted to individual needs
Number of subjects: 80
Study 6421429 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic diet with an osmolality of 430 mmol/kg (group 1)
Number of subjects: 118
Study 6421429 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with osmolality increasing from 145 to 430 mmol/kg over the first four days (group 2)
Number of subjects: 118
Study 6421429 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic diet (300 mmol/kg) (group 3)
Number of subjects: 118
Study 6421429 — intervention group
Group type: COMPARATOR
Intervention: All diets (group 1, group 2, group 3)
Number of subjects: 118
Study 6421429 — intervention group
Group type: COMPARATOR
Intervention: Concurrent treatment with antibiotics
Number of subjects: 118
Study 3555277 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral bisacodyl
Number of subjects: 45
Study 3555277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31758523 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation and intensive education (CRIE) program
Number of subjects: 300
Study 31758523 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 300
Study 31322838 — intervention group
Group type: EXPERIMENTAL
Intervention: Alutard SQ (Dp extracts)
Number of subjects: 230
Study 31322838 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoHelisen Depot (NHD; Dp/Df extracts)
Number of subjects: 230
Study 28753075 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive messages
Number of subjects: 199
Study 28753075 — intervention group
Group type: COMPARATOR
Intervention: Autonomy support
Number of subjects: 199
Study 26578326 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting intervention
Number of subjects: 51
Study 23307845 — intervention group
Group type: EXPERIMENTAL
Intervention: EB/TBA (14 mg estradiol benzoate and 100 mg trenbolone acetate)
Number of subjects: 12
Study 23307845 — intervention group
Group type: EXPERIMENTAL
Intervention: EB (14 mg estradiol benzoate)
Number of subjects: 12
Study 23307845 — intervention group
Group type: EXPERIMENTAL
Intervention: TBA (100 mg trenbolone acetate)
Number of subjects: 12
Study 23307845 — intervention group
Group type: COMPARATOR
Intervention: Sham-implanted control (SC)
Number of subjects: 12
Study 23307845 — intervention group
Group type: EXPERIMENTAL
Intervention: EB/TBA
Number of subjects: 12
Study 23307845 — intervention group
Group type: EXPERIMENTAL
Intervention: TBA
Number of subjects: 12
Study 23307845 — intervention group
Group type: EXPERIMENTAL
Intervention: EB and TBA
Number of subjects: 12
Study 21138981 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR ≥60
Number of subjects: 86
Study 21138981 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR 59‐30
Number of subjects: 86
Study 21138981 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <30
Number of subjects: 86
Study 18438255 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (total body session, circuit fashion, 7 exercises, 3 circuits of 8 to 12 RM, abdominal exercise 15 to 20 RM)
Number of subjects: 20
Study 18438255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 17070196 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/d)
Number of subjects: 74
Study 17070196 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) (100 mg/d)
Number of subjects: 74
Study 12075708 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear topical ointment
Number of subjects: 40
Study 12075708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ointment)
Number of subjects: 40
Study 12075708 — intervention group
Group type: COMPARATOR
Intervention: Both groups (treatment and control)
Number of subjects: 40
Study 9861383 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclabendazole, 5 mg/kg once daily for 3 days
Number of subjects: 62
Study 9861383 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclabendazole, 10 mg/kg twice on one day
Number of subjects: 62
Study 9861383 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclabendazole, 10 mg/kg in a single dose
Number of subjects: 62
Study 9861383 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel, 25 mg/kg thrice daily for 3 days
Number of subjects: 62
Study 9861383 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 62
Study 9861383 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclabendazole
Number of subjects: 62
Study 9861383 — intervention group
Group type: EXPERIMENTAL
Intervention: By day 90
Number of subjects: 62
Study 9861383 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 10 mg/kg
Number of subjects: 62
Study 9861383 — intervention group
Group type: EXPERIMENTAL
Intervention: By day 365
Number of subjects: 62
Study 7632447 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT program (enhanced intervention program)
Number of subjects: 252
Study 7632447 — intervention group
Group type: COMPARATOR
Intervention: Regular screening and referral group (control)
Number of subjects: 252
Study 2167564 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBV
Number of subjects: 20
Study 2167564 — intervention group
Group type: COMPARATOR
Intervention: smallpox vaccine
Number of subjects: 20
Study 736080 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular drops of 10% phenylephrine HCl and 1.0% cyclopentolate HCl or 1.0% tropicamide HCl
Number of subjects: 0
Study 736080 — intervention group
Group type: COMPARATOR
Intervention: Microdrops (0.005 or 0.01 ml) of a mixture of 5% phenylephrine HCl and 0.5% tropicamide HCl
Number of subjects: 0
Study 736080 — intervention group
Group type: COMPARATOR
Intervention: Regular drops of mixtures of 1% phenylephrine HCl or 0.4% hydroxyamphetamine hydrobromide with 0.1% cyclopentolate HCl or 0.1% tropicamide
Number of subjects: 0
Study 736080 — intervention group
Group type: COMPARATOR
Intervention: Diluted solutions (0.005 or 0.01 ml)
Number of subjects: 0
Study 29064343 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS-based functional exercise plus routine rehabilitation (Group 1)
Number of subjects: 38
Study 29064343 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation only (Group 2)
Number of subjects: 38
Study 27449546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 101
Study 27449546 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study 25842934 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-related kidney transplantation (group 1, 50 patients)
Number of subjects: 80
Study 25842934 — intervention group
Group type: COMPARATOR
Intervention: Cadaver kidney transplantation (group 2, 30 patients)
Number of subjects: 80
Study 25842934 — intervention group
Group type: COMPARATOR
Intervention: Cadaver kidney transplantation with rapid recovery (group 2a, 20 patients)
Number of subjects: 80
Study 25842934 — intervention group
Group type: COMPARATOR
Intervention: Cadaver kidney transplantation with delayed recovery (group 2b, 10 patients)
Number of subjects: 80
Study 25842934 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis sessions in group 2b
Number of subjects: 80
Study 23208965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric commercial formula (Optisource®) - 1109.3 kcal/day, 166.4 g carbohydrates, 63 g proteins, 21.3 g lipids
Number of subjects: 40
Study 23208965 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutritional advice (decrease 500 cal/day)
Number of subjects: 40
Study 20833591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg twice daily)
Number of subjects: 2757
Study 20833591 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (81 mg once daily)
Number of subjects: 2757
Study 18656091 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg daily
Number of subjects: 2838
Study 18656091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study 17094914 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAC combined with preoperative radiotherapy (radiochemotherapy group)
Number of subjects: 60
Study 17094914 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy alone (radiotherapy group)
Number of subjects: 60
Study 17094914 — intervention group
Group type: COMPARATOR
Intervention: Operation alone (control group)
Number of subjects: 60
Study 12829200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with hydrocortisone (5 mg/d) and fludrocortisone (50 microg/d)
Number of subjects: 100
Study 10484047 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) levels in subjects with neuropathy
Number of subjects: 452
Study 10484047 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) levels in subjects with macroalbuminuria
Number of subjects: 452
Study 10484047 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of tHcy with serum creatinine
Number of subjects: 452